Emotion processing in the minimally conscious state

As a newly described condition distinct from coma or the vegetative state, minimally conscious state (MCS) is characterised by a threshold level of consciousness, and diagnostic criteria have recently been proposed. In MCS, cognitively mediated behaviour occurs inconsistently, but is reproducible or sustained enough to be differentiated from reflexive behaviour. It is clinically essential to distinguish this condition from persistent vegetative state (PVS), due to a potentially more favourable outcome. So far, whether patients in MCS can process emotion is unknown.

Cortical processing has been described in PVS using auditory and visual functional paradigms with positron emission tomography. However, to date hardly any functional imaging studies are available in patients in MCS. We used fMRI to assess brain activity induced by an emotional stimulus in a patient in MCS.

A 17 year old man was riding his bicycle when he was hit by a train. The accident resulted in head trauma and immediate coma, progressing to MCS over the course of 4 months, when he was admitted to our institution. This research protocol was approved by the Institutional Ethics Committee. At the time of the fMRI study, 5 months after the accident, the patient localised noxious stimuli, had spontaneous eye opening, detectable sleep/wake cycles, sustained visual fixation, and contingent smiling, thus meeting criteria for MCS. A structural MRI study showed mild cortical atrophy and dilated ventricles. Auditory evoked potentials showed decreased conduction velocities at brainstem level. The patient increased his level of awareness 2.5 months after the functional study was conducted. Auditory evoked potentials after recovery were within normal range, while MRI showed much less ventricle dilatation. Six months after recovering full consciousness, he was able to chat normally and feed himself. Currently we are retesting the patient with the same paradigm.

Non-familiar voice v silence and mother’s voice v non-familiar voice recognition were tested in an fMRI block design with 30 seconds per epoch. The patient listened to his mother reading a story, followed 30 seconds later by an age matched voice reading the same story, for 30 seconds with silence epochs in between. Blood oxygen level dependent images were acquired using a T2 weighted gradient echo planar sequence on a General Electric Signa CVI, 1.5T system with real time image processing of multislice and multi-phase images during patient stimulation and rest periods. The Medx 3.4 Sensor System was used to carry out fMRI post-processing, including motion correction and Gaussian smoothing. An uncorrected significance threshold of P<0.001 was used because amygdala and insula activation was expected, owing to emotional voice processing. Activated clusters were localised following co-registration with an anatomical T1-IR volume.

Subtraction of the phrases read by the age matched voice from silence was the control experiment, showing a significant focus of activation in the transverse and superior temporal gyrus, which spread to the planum temporale; more anterior activation was found in the superior (right) and inferior (left) insula (fig 1A). The subtraction of the mother’s phrases from the age matched voice disclosed a strong activation of the amygdala and insula spreading to the inferior frontal gyrus; there was also weaker activation of the transverse temporal gyrus, temporal operculum, and planum temporale (fig 1B,C). Activation was lower on the right hemisphere in both comparisons, non-familiar voice v silence and familiar voice v non-familiar.

To the best of our knowledge, our results provide for the first time anatomical evidence for the response of an MCS patient to a familiar voice, in which both amygdala and insula appear to play a major role.

The activation pattern of the control experiment agrees with previous studies. Our results showed that the mother’s voice activates the extended amygdala, an emotionally related structure, and a directly connected area such as the insula, perhaps acting jointly as limbic integration cortex. Although residual cerebral activity was unequivocal in our case, representing fragmentary cognitive processing, it should not be assumed that it depicts a fully integrated system required for normal levels of awareness; however, our findings highlight the legal and ethical implications of careless bedside chatter. Whether functional imaging represents a reliable method to evaluate neural processing in MCS patients, in whom cognitive output is extremely difficult to assess, remains to be seen.

References


Figure 1  Brain areas of activation produced by non-familiar voice subtracted from silence in coronal view (control experiment, A). Brain areas of activation produced by mother’s voice subtracted from non-familiar voice in coronal view (B), and in axial view (C)
Neurosyphilis presenting with gummatous oculomotor nerve palsy

Although epidemiological studies suggest that the incidence of primary syphilis is rising, neurosyphilis remains an uncommon manifestation of Treponema pallidum infection. In addition, the MRI appearances of this treatable neurological condition are not well known. Many patients with neurosyphilis are asymptomatic, but manifestations include subacute basilar meningitis, a meningovascular syndrome caused by small vessel cerebral and cranial nerve infarctions, and chronic gummatous inflammation with focal intracranial mass lesions, chronic comportmental dementia of general paresis, and chronic sensory-ataxic myelopathy of tabes dorsalis. We report a case in which a meningeal form of neurosyphilis presented with rapid evolution of a pupil-involving oculomotor nerve palsy to highlight the clinical, CSF, and MRI features and good response to treatment.

Case report

The patient was a 54 year old right handed homosexual man with a history of syphilis of unknown stage, treated with penicillin 25 years previously. He was well until 6 weeks prior to evaluation when he sustained minor head trauma in an automobile accident, followed by intermittent headaches, fatigue, photophobia, and anorexia. Four days before admission he developed worsening and persistent drooping of the right eyelid and double vision. On examination, his mental status was remarkable only for psychomotor slowing. The right pupil was round but enlarged at 6 mm and sluggishly constricted to 5 mm with direct and consensual light stimulation as well as near vision. The left pupil was round and 4 mm and constricted briskly to light. The right eye showed a moderate ptosis of the upper lid, and the globe was deviated laterally in primary gaze with markedly impaired adduction and elevation. In the left eye, ptosis was absent and oculomotor motility was normal. Other cranial nerve, sensory, motor, and reflex functions and gait were normal with the exception of a slight decrease in vibration and position sense in the feet. There were no signs of meningial irritation. Head computed tomography (CT) and CT angiography revealed no blood in the subarachnoid space nor evidence of intracranial aneurysm. MRI of the head (fig 1) showed a spheroid contrast-enhancing lesion at the root of the right oculomotor nerve, which extended towards the cavernous sinus. Incidentally noted were right cerebellar and right frontolateral venous anomalies. CSF examination revealed normal opening pressure at lumbar puncture, 344 white blood cells (WBCs) (95% lymphocytes), 14 red blood cells (RBCs), protein of 167 mg%, and glucose of 39 mg%. CSF Venereal Disease Research Laboratory test (VDRL) and serum RPR titres were unchanged. At 6 months, no additional improvement in oculomotor nerve functions was seen but fatigue had subsided. Repeat MRI 7 months after hospital admission showed complete resolution of the oculomotor nerve abnormality.

Discussion

Neurosyphilis is known to cause oculomotor nerve palsies either in the meningovascular phase, due to small vessel vasculitis with resultant nerve infarction, or in granulomatous basilar meningitis, due to inflammation of the nerve or its investiture; however, the literature on syphilitic mass lesions around the oculomotor nerve is sparse. Vogl et al reported a case of oculomotor nerve palsy caused by gummatous neurosyphilis: MR findings. J Clin Neuroophthalmol 1993; 3(3):139–43.

The lesion in our patient was isointense to adjacent brain on T1 and T2 MR sequences, with normal opening pressure at lumbar puncture, protein of 167 mg%, and glucose of 39 mg%. CSF VDRL and serum RPR titres were unchanged. At 6 months, no additional improvement in oculomotor nerve functions was seen but fatigue had subsided. Repeat MRI 7 months after hospital admission showed complete resolution of the oculomotor nerve abnormality.

References


High dose cyclophosphamide for severe refractory myasthenia gravis

Myasthenia gravis (MG) exemplifies autoimmune disease. Most patients require immunomodulating treatment, including steroids, chemotherapy, or intravenous immunoglobulin (Ig), in addition to anticholinesterase

www.jnnp.com
Materials and methods
All patients participated in studies approved by the Drexel University College of Medicine and signed informed consent. These three patients with severe (class IVb) refractory MG includes all patients treated. Patients received cyclophosphamide 50 mg/kg (adjusted ideal body weight)/day over four consecutive days. Patients received antibacterial, antiviral, and antifungal prophylaxis. Haemorrhagic cystitis prophylaxis included Mesna and forced diuresis. Packed red cells and platelets were transfused to maintain haemoglobin >8.5 g/dL and platelets >10 x 10^9/L.

Results
Patient 1 was diagnosed with seronegative MG at 30 years of age by a positive tensilon test and a decremental response on repetitive stimulation. Pyridostigine was initiated. He underwent high dose cyclophosphamide without stem cell rescue.

Treatment course
Patient 1 had 13 days of neutropenia, required three units of packed red cells and three platelet transfusions. Patient 2 had 9 days of neutropenia, required two units of packed red cells, and three platelet transfusions. Patient 3 had 11 days of neutropenia, required five units of packed red cells, and two platelet transfusions. Patients 1 and 3 experienced MG flares requiring intravenous Ig and plasmapheresis, but neither required intubation.

Neurological follow up
Patient 1, intubated 27 times before treatment, required a single intubation during 48 months of follow up. To control less severe exacerbations, during the first 40 months after immunoablative treatment, oral cyclophosphamide was necessary. She continues to evaluate the duration effect and time to maximum benefit of this treatment. Patient 2 had an early and sustained response to treatment. Her serum AChr levels did not correlate with disease activity during the follow up periods.

Discussion
Patients discussed have all suffered from severe refractory MG, which requires multiple intubations. All underwent thymectomy: patients 1 and 3 repeat thymectomies. Patient 2 had an early and sustained response to treatment. Patients 1 and 3 had multiple exacerbations. As this treatment targets IgG production, exacerbations following treatment are expected. Patient 1, who required 27 intubations before treatment and only once since, and who has in the past 6 months stopped oral cyclophosphamide, may yet to enjoy the maximum benefit of this treatment. Patient 3, one year after treatment, has an improving activity level. The intervals between exacerbations are increasing: 5, 8, and 11 weeks. It is 26 weeks since her last exacerbation.

Recently, Drachman et al published a single institution case series of three patients with refractory MG who were also treated with high dose cyclophosphamide. In this series, one patient had AChR antibody negative MuSK antibody positive myasthenia. Their mean disease duration was 10.3 (range: 3–15) years; one required intubation and median follow up was 24 (range: 7–40) months. In comparison, in the three patients described here, two had antibody negative myasthenia and the mean disease duration was 16.3 (range: 9–29) years. All required multiple intubations: 27, 2, and 11, and our median follow up is 25 (range: 13–48) months. During follow up, patient 3’s serum AChr levels remained undetectable and did not correlate with her clinical course. Drachman et al reported a decline in antibody levels in their patients treated in a similar way, although AChr antibody titres and MuSK antibodies persisted in their patients even after 2 years. This suggests that long term remissions in MG may be possible even without achieving complete immunoablation. High dose cyclophosphamide has the potential to significantly reduce symptoms and increase life quality among people with MG refractory compared to conventional treatment. Long term follow up is necessary to evaluate the duration effect and time to maximum benefit. High dose cyclophosphamide treatment warrants further study as a treatment for severe refractory MG.

Table 1 Patient characteristics before high dose cyclophosphamide treatment

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>Patient 1 41/female</th>
<th>Patient 2 56/male</th>
<th>Patient 3 41/female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of MG (y)</td>
<td>11</td>
<td>9</td>
<td>29</td>
</tr>
<tr>
<td>MG severity class</td>
<td>IVb</td>
<td>IVb</td>
<td>IVb</td>
</tr>
<tr>
<td>AChr (ng/mL)</td>
<td>Undetectable</td>
<td>Undetectable</td>
<td>Undetectable</td>
</tr>
<tr>
<td>Previous treatment</td>
<td>Pyridostigmine</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Thymectomy (yes)</td>
<td>2</td>
<td>1</td>
<td>X</td>
</tr>
<tr>
<td>iv Ig (no of infusions)</td>
<td>1</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Prednisone (mg)</td>
<td>10–100 mg qd, duration 3 years</td>
<td>40–100 mg qd, duration 7 years</td>
<td>10–60 mg qd, duration 4 years</td>
</tr>
<tr>
<td>Plasmapheresis (no of procedures)</td>
<td>2</td>
<td>7</td>
<td>16</td>
</tr>
<tr>
<td>Azathioprine (mg)</td>
<td>50 mg/d, duration 12 months</td>
<td>200 mg qd, duration 2 months</td>
<td>50–150 mg qd, duration 15 months</td>
</tr>
<tr>
<td>Oral cyclophosphamide</td>
<td>100 mg qd, 28 months</td>
<td>200 mg qd, duration 2 months</td>
<td>250–500 mg qd, duration 7 months</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>50–125 mg bid, duration 3 months</td>
<td>50–125 mg bid, duration 3 months</td>
<td>50–125 mg bid, duration 3 months</td>
</tr>
<tr>
<td>Cellcept</td>
<td>125 mg qd, duration 3 months</td>
<td>125 mg qd, duration 3 months</td>
<td>125 mg qd, duration 3 months</td>
</tr>
</tbody>
</table>

MG: myasthenia gravis; iv, intravenous; Ig, immunoglobulin; qd, four times daily; bid, twice daily

MG resulted in two intubations. After thymectomy revealed a 75 g lipoma. His AChr titres were 78. He continued on pyridostigmine and prednisone (25–40 mg daily) was required. At 54 years of age, CIDP was diagnosed. Despite steroids (plasmapheresis, intravenous Ig, azathioprine, and pyridostigmine) he continued to have symptoms of double vision, dysphonia, and dysphagia with a continued decremental response to repetitive stimulation. At 56 years of age, he underwent high dose cyclophosphamide without stem cell rescue.

Patient 3 was diagnosed with antibody positive MG at 12 years of age, initially treated with pyridostigmine. She received her first thymectomy at age 18 years and continued on pyridostigmine and occasional steroids. By 36 years of age, she was steroid dependent. Between ages 38 and 41 years she required 11 intubations and only transiently responded to intravenous Ig and plasmapheresis. A second thymectomy was performed at age 39 and cyclosporine (CsA) was initiated. She continued on prednisone 25 mg qod, scheduled intravenous Ig every 3–4 weeks, and intermittent plasmapheresis. The CsA and Cellcept were maintained but poorly tolerated. At 41 years of age, she underwent high dose cyclophosphamide without stem cell rescue.

Patient 2 had myasthenic symptoms of dysphagia and diplopia. Seven months after treatment pyridostigmine was stopped and after 12 months prednisone was stopped. Twenty five months after treatment, his MG is in full remission.

Patient 3 experienced five flares at 1, 6, 11, 19, and 30 weeks following treatment. The exacerbations at 1, 6, and 11 weeks required intravenous Ig and steroids; exacerbations at 19, and 30 weeks required plasmapheresis. Her last exacerbation necessitated intubation. Between exacerbations her functional ability consistently improved. She stopped steroids at 50 weeks. At 52 weeks, a slow pyridostigmine taper began. Her serum AChr levels did not correlate with disease activity during the follow up periods.
Acute head drop after cervical hyperflexion injury

Head drop is familiar to neurologists, but not widely appreciated by neurosurgeons. There are multiple causes of this condition1,2 in which the patient is unable to hold their head up because of weakness of the neck extensor musculature. It predominantly results from primary muscle pathologies in the neck extensor muscles, with occasional evidence supporting a neurogenic aetiology.3 4 I describe three patients in whom acute head drop closely followed cervical hyperflexion injury, and suggest that the cause is bilateral traction neuropathy of one or more cervical dorsal rami.

Patient A was an 84 year old man who enjoyed excellent health prior to falling backwards, striking his occiput on a wall and sustaining forced flexion of the cervical spine. He complained of posterior cervical pain but, when seen in casualty for closure of an occipital laceration, was found to be neurologically intact. Cervical x-rays showed only degenerative disease in the mid-lower cervical spine and loss of lordosis. Over 2 weeks the pain in his neck resolved, but he became aware of a difficulty holding his head up as the day progressed and, later, of aching in his neck extensor muscles. He was referred to neurosurgery as a possible case of delayed malignment at C4/5 never progressed, nor did any neurological deficits develop.

Patient B was a fit 72 year old man who sustained a flexion/extension whiplash injury during a road traffic accident (RTA). In casualty, he had minor neck pain but was neurologically intact and had cervical x-rays showing only minor degenerative changes and loss of lordosis. He was managed with analgesics and a Philadelphia collar. 6 days later he returned to casualty complaining of aching in his neck and progressive difficulty in holding up his head throughout the day. Neurological examination revealed that his cervical x-rays showed angulation into 7° of flexion at C5/6, but were otherwise unchanged. He was referred to neurosurgery and at review was strikingly reminiscent of patient A. He had to hold his chin up with a hand to look ahead, had pain in the back of his neck, which developed over the day unless he used his collar, and was neurologically normal, including in the cervical dermatomes. Magnetic resonance imaging (MRI) of his neck revealed normal soft tissue anatomy. A neurological opinion confirmed the normal examination, other than head ptosis. There was no evidence of inflammatory, auto-immune, or infectious, or biochemically, the Tensilon test was negative, and serum creatine kinase was normal. There were no features of Parkinson’s disease or amyotrophic lateral sclerosis (ALS). Electroneuromyography (EMG) studies of the neck muscles performed 3 weeks after injury were normal in the ventral muscles, but there were typical features of acute partial denervation in the neck extensors bilaterally, particularly in a band in the mid- to low cervical spine with more normal EMGs above and below this. However, electrophysiological examination of the limbs was abnormal also and consistent with an asymptomatic peripheral neuropathy.

The patient declined muscle or nerve biopsy.

In view of patient A’s course and the evidence in patient B of acute denervation that might recover, patient B was managed expectantly, as patient A had been used to maintain range of neck movement and encourage use of the neck extensor muscles. He was given a Philadelphia collar, which was worn by day once he became aware of head ptosis. This was progressively recovered to normal over 4 months, including recovery of the spinal alignment at C5/6, and the Philadelphia collar was withdrawn. There has been no recurrence of head ptosis.

Patient C, a 54 year old man, was similar to patient A. He suffered a whiplash injury in an RTA and developed head ptosis and angulation at C5/6 on cervical x-rays 2 weeks later. Investigation and management mirrored patient B. His EMG was normal of his neck extensor muscle EMG, which suggests partial denervation, but otherwise was normal clinically, biochemically, and electrophysiologically. We did not suggest muscle or nerve biopsy as it was clear he would be managed conservatively, with biotherapy and external bracing, patient C made a complete recovery in 2 months, including recovery of spinal alignment at C5/6. There was no recurrence of head ptosis.

Although there are reports of head drop in conditions predominantly affecting neural rather than muscular elements,18 19 20 21 Umapathi et al22 cite Braun et al,23 who treat refractory torticollis (response to multiple cervical dorsal rami without generating significant functional deficits, as evidence that focal
deviation of neck extensor muscles is unlikely to cause head ptosis. This surgical denervation, however, is unilateral and the denervated muscles are liable to grossly abnormal because of secondary changes resulting from the underlying condition. The cat neck extensor muscle biventer cervicis (analogous to human semispinalis capitis) has tenuous innervations defining serially arranged compartments, each receiving segmental innervation from a cervical dorsal ramus. The muscle only generates useful tension if all compartments are co-stimulated; unstimulated compartments act as weak springs in serial series and dissipate the muscle.24 There is some evidence for similar architecture in human neck extensors: they receive innervation from several cervical dorsal rami25 and have tendinous inscriptions producing several at least partially serial compartments.26 Denervation of one compartment bilaterally would produce significant weakness and fatigability in such compartmentalised muscles. Additionally, the deeper muscles only traverse one motion segment and are innervated by one posterior primary ramus. Segmental denervation of either type of muscle would lead to angulation at a motion segment, limited in degree by intact joints, ligaments, and disc space.

Whiplash injury can cause neurapraxia of cranial nerve XI, XII, and branches of the cervical plexus,27 28 and there are other reports of traction neuropathies in the neck.29 In the present cases, the close temporal relationship of the head drop to a forced flexion injury and the EMG findings suggesting acute denervation of neck extensor muscles are consistent with a neurogenic mechanism.

Although dystonia of neck flexor muscles can produce head drop, these patients could easily lift their chins and there was no evidence of ventral neck muscle hypertonia on clinical examination. In addition, in patients B and C, there were normal EMG findings in the ventral neck muscles but abnormal findings in the neck extensors.

Neurapraxia of dorsal primary rami would be expected to recover in time, but it is inconceivable that sufficient fibres would have been torn to produce head drop without also producing soft tissue abnormalities of the neck. This is not the case. Only two of the cases were investigated to exclude primary neurological disorders. These were excluded in patient C. Although patient B had evidence of a pre-existing peripheral neuropathy, this may simply have made him more prone to traction neurapraxia after whiplash and his eventual recovery is consistent with the proposed mechanism.

It is unclear why this syndrome has not been described before. Perhaps most whiplash injuries produce insufficient neurapraxia to provoke head drop unless patient factors adversely affect the transmission of forces to the nerves or their susceptibility to injury. In non-predisposed individuals, sufficiently severe injuries might instead produce fractures/dislocations, whose management masks signs of a concomitant neurapraxia. Less severe injuries might produce a transient drop, which is either not recognised or recovers quickly and never requires secondary referral. Furthermore, although motor deficits may be rare after whiplash, sensory symptoms may be common and may simple the patient’s symptoms in a case of “typical” whiplash syndrome. There is support for this
We report a case of acute disseminated encephalomyelitis (ADEM) temporally associated with *Campylobacter* gastroenteritis in a previously fit man. A MedLine search using the keywords “ADEM”, “demyelination”, and “campylobacter” revealed no previous reports of ADEM associated with *Campylobacter* infection in isolation.

A 24 year old man presented to his general practitioner with a 2 day history of non-bloody diarrhoea associated with fevers and sweats. His past medical history was unremarkable. He drank 6 units of alcohol per week and smoking status was unknown. His general practitioner prescribed loperamide for symptomatic relief. The patient was admitted to hospital complaining of headache, fever, and sweats. Examination revealed a temperature of 38.4°C, pulse of 65 beats/min and normal blood pressure. Rectal examination revealed hard stool. There were no focal neurological signs. His haemoglobin was 15.3 g/dl, leucocyte count was 13.3 x 10^9/L (87.1% neutrophils) and C-reactive protein was 12.8 mg/L. Two days after admission (day 16 of illness), the patient reported a change in his personality and he complained of slurring of speech, intermittent diplopia, and difficulty in walking. Examination revealed mild dysthria, left sided facial weakness, mild left pyramidal limb weakness, and decreased sensation in the left leg. Tendon reflexes were brisk but plantar responses were flexor. His gait was ataxic. Cranial CT scan showed no significant abnormalities. Lumbar puncture revealed an opening pressure of 160 mm CSF, total cell count of 34/mm^3 with a white cell count of 20/mm^3 (100% lymphocytes), total protein of 541 mg/L, glucose of 3.2 mmol/L, and negative oligoclonal bands. CSF findings included mononuclear pleocytosis and mild protein elevation. There were few data available on evidence based treatment regimens, but treatment is usually instituted with high dose glucocorticoids. Plasmapheresis and intravenous immunoglobulin have also been used. *Campylobacter* gastroenteritis is the most common cause of acute gastroenteritis in the UK, accounting for over 56 000 cases in 2000. Its incidence has risen progressively over the past 2 decades. In the majority of cases, the illness self terminates within a few days with no long term consequences. It is estimated that approximately 1/1000 reported campylobacteriosis cases lead to Guillain-Barré syndrome, and around 33% of Guillain-Barré syndrome cases in the UK may be triggered by campylobacteriosis. Huber et al reported a case of combined ADEM and acute motor axonal neuropathy following *Campylobacter jejuni* infection and hepatitis. A immunisation-related multiple sclerosis case was described. MRI scans showed a slight enhancement in the left cerebral peduncle that disappeared when the study was repeated a week later. Nasralla et al reported a case of postinfectious encephalomyelitis in a patient with *Campylobacter jejuni* enteritis. Cranial MRI scanning showed a combination of predominate grey matter involvement with concomitant focal areas of subcortical white matter lesions with no parenchymal enhancement, to which the authors felt to be different from the pattern of signal abnormalities seen in patients with ADEM. The MRI abnormalities in our case were in keeping with ADEM although, as with the case reported by Huber et al, the amount of enhancement was minimal, indicating that the majority of the lesions were not acute. The paucity of reported cases of ADEM following *Campylobacter* infection is surprising given the high reported association between *Campylobacter jejuni* infection and Guillain-Barré syndrome and the pathogenesis of the latter. In these cases, *Campylobacter jejuni* induces humeral and cellular immune responses due to molecular mimicry with specific lipopolysaccharide epitopes on the infecting agent and target epitopes on the nervous system structures alone or in synergy with antibiotics. Viral or bacterial superantigens could likewise trigger autoreactive T cells with similar results.

The diagnosis of ADEM is usually made clinically with the aid of MRI scanning, lumbar puncture finding and electrophysiological studies. MRI scanning reveals multiple areas of increased signal on T2 weighted images in the white matter throughout the central nervous system, most being located in the subcortical white matter of both hemispheres, which are often quite extensive and enhance with contrast. CSF findings include mononuclear pleocytosis and mild protein elevation. There are few data available on evidence based treatment regimens, but treatment is usually instituted with high dose glucocorticoids. Plasmapheresis and intravenous immunoglobulin have also been used. *Campylobacter* gastroenteritis is the most common cause of acute gastroenteritis in the UK, accounting for over 56 000 cases in 2000. Its incidence has risen progressively over the past 2 decades. In the majority of cases, the illness self terminates within a few days with no long term consequences. It is estimated that approximately 1/1000 reported campylobacteriosis cases lead to Guillain-Barré syndrome, and around 33% of Guillain-Barré syndrome cases in the UK may be triggered by campylobacteriosis. Huber et al reported a case of combined ADEM and acute motor axonal neuropathy following *Campylobacter jejuni* infection and hepatitis. A immunisation-related multiple sclerosis case was described. MRI scans showed a slight enhancement in the left cerebral peduncle that disappeared when the study was repeated a week later. Nasralla et al reported a case of postinfectious encephalomyelitis in a patient with *Campylobacter jejuni* enteritis. Cranial MRI scanning showed a combination of predominate grey matter involvement with concomitant focal areas of subcortical white matter lesions with no parenchymal enhancement, to which the authors felt to be different from the pattern of signal abnormalities seen in patients with ADEM. The MRI abnormalities in our case were in keeping with ADEM although, as with the case reported by Huber et al, the amount of enhancement was minimal, indicating that the majority of the lesions were not acute. The paucity of reported cases of ADEM following *Campylobacter* infection is surprising given the high reported association between *Campylobacter jejuni* infection and Guillain-Barré syndrome and the pathogenesis of the latter. In these cases, *Campylobacter jejuni* induces humeral and cellular immune responses due to molecular mimicry with specific lipopolysaccharide epitopes on the infecting agent and target epitopes on the nervous system structures alone or in synergy with antibiotics. Viral or bacterial superantigens could likewise trigger autoreactive T cells with similar results.

The diagnosis of ADEM is usually made clinically with the aid of MRI scanning, lumbar puncture finding and electrophysiological studies. MRI scanning reveals multiple areas of increased signal on T2 weighted images in the white matter throughout the central nervous system, most being located in the subcortical white matter of both hemispheres, which are often quite extensive and enhance with contrast. CSF findings include mononuclear pleocytosis and mild protein elevation. There are few data available on evidence based treatment regimens, but treatment is usually instituted with high dose glucocorticoids. Plasmapheresis and intravenous immunoglobulin have also been used. *Campylobacter* gastroenteritis is the most common cause of acute gastroenteritis in the UK, accounting for over 56 000 cases in 2000. Its incidence has risen progressively over the past 2 decades. In the majority of cases, the illness self terminates within a few days with no long term consequences. It is estimated that approximately 1/1000 reported campylobacteriosis cases lead to Guillain-Barré syndrome, and around 33% of Guillain-Barré syndrome cases in the UK may be triggered by campylobacteriosis. Huber et al reported a case of combined ADEM and acute motor axonal neuropathy following *Campylobacter jejuni* infection and hepatitis. A immunisation-related multiple sclerosis case was described. MRI scans showed a slight enhancement in the left cerebral peduncle that disappeared when the study was repeated a week later. Nasralla et al reported a case of postinfectious encephalomyelitis in a patient with *Campylobacter jejuni* enteritis. Cranial MRI scanning showed a combination of predominate grey matter involvement with concomitant focal areas of subcortical white matter lesions with no parenchymal enhancement, to which the authors felt to be different from the pattern of signal abnormalities seen in patients with ADEM. The MRI abnormalities in our case were in keeping with ADEM although, as with the case reported by Huber et al, the amount of enhancement was minimal, indicating that the majority of the lesions were not acute. The paucity of reported cases of ADEM following *Campylobacter* infection is surprising given the high reported association between *Campylobacter jejuni* infection and Guillain-Barré syndrome and the pathogenesis of the latter. In these cases, *Campylobacter jejuni* induces humeral and cellular immune responses due to molecular mimicry with specific lipopolysaccharide epitopes on the infecting agent and target epitopes on the nervous system structures alone or in synergy with antibiotics. Viral or bacterial superantigens could likewise trigger autoreactive T cells with similar results.

The diagnosis of ADEM is usually made clinically with the aid of MRI scanning, lumbar puncture finding and electrophysiological studies. MRI scanning reveals multiple areas of increased signal on T2 weighted images in the white matter throughout the central nervous system, most being located in the subcortical white matter of both hemispheres, which are often quite extensive and enhance with contrast. CSF findings include mononuclear pleocytosis and mild protein elevation. There are few data available on evidence based treatment regimens, but treatment is usually instituted with high dose glucocorticoids. Plasmapheresis and intravenous immunoglobulin have also been used. *Campylobacter* gastroenteritis is the most common cause of acute gastroenteritis in the UK, accounting for over 56 000 cases in 2000. Its incidence has risen progressively over the past 2 decades. In the majority of cases, the illness self terminates within a few days with no long term consequences. It is estimated that approximately 1/1000 reported campylobacteriosis cases lead to Guillain-Barré syndrome, and around 33% of Guillain-Barré syndrome cases in the UK may be triggered by campylobacteriosis. Huber et al reported a case of combined ADEM and acute motor axonal neuropathy following *Campylobacter jejuni* infection and hepatitis. A immunisation-related multiple sclerosis case was described. MRI scans showed a slight enhancement in the left cerebral peduncle that disappeared when the study was repeated a week later. Nasralla et al reported a case of postinfectious encephalomyelitis in a patient with *Campylobacter jejuni* enteritis. Cranial MRI scanning showed a combination of predominate grey matter involvement with concomitant focal areas of subcortical white matter lesions with no parenchymal enhancement, to which the authors felt to be different from the pattern of signal abnormalities seen in patients with ADEM. The MRI abnormalities in our case were in keeping with ADEM although, as with the case reported by Huber et al, the amount of enhancement was minimal, indicating that the majority of the lesions were not acute. The paucity of reported cases of ADEM following *Campylobacter* infection is surprising given the high reported association between *Campylobacter jejuni* infection and Guillain-Barré syndrome and the pathogenesis of the latter. In these cases, *Campylobacter jejuni* induces humeral and cellular immune responses due to molecular mimicry with specific lipopolysaccharide epitopes on the infecting agent and target epitopes on the nervous system structures alone or in synergy with antibiotics. Viral or bacterial superantigens could likewise trigger autoreactive T cells with similar results.
surface components of the peripheral nerves, resulting in myelin destruction and axonal degeneration.7 Furthermore, patients with ADEM often have peripheral nervous system involvement and there have been occasional cases of ADEM associated with Guillain-Barré syndrome. Our patient did not have any clinical features suggestive of peripheral nervous system involvement. However, nerve conduction studies were not performed and a degree of sub-clinical neuropathy cannot therefore be excluded.

We describe the first identifiable case of ADEM temporally associated with Campylobacter gastroenteritis alone. Our patient made an excellent recovery associated with therapy with high dose methylprednisolone.

Acknowledgements
We are most grateful to Dr D Connolly for reviewing the MRI imaging.

References

Figure 1 Axial T2 weighted image showing supra- and infra-tentorial high signals in both hemispheres, and coronal T1 weighted images showing peri-trigonal white matter lesions with slight enhancement following intravenous gadolinium DTPA injection in keeping with ADEM.

D Orr, M W McKendrick
Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield, UK

B Sharrack
Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK
doi: 10.1136/jnnp.2003.013433

Competing interests: none declared

Received 26 February 2003
Revised 14 July 2003
Accepted 19 August 2003

www.jnnp.com
Emotion processing in the minimally conscious state

T Bekinschtein, J Niklison, L Sigman, F Manes, R Leiguarda, J Armony, A Owen, S Carpintiero and L Olmos

J Neurol Neurosurg Psychiatry 2004 75: 788
doi: 10.1136/jnnp.2003.034876

Updated information and services can be found at:
http://jnnp.bmj.com/content/75/5/788

These include:

References
This article cites 5 articles, 2 of which you can access for free at:
http://jnnp.bmj.com/content/75/5/788#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/75/7/1086.4.full.pdf

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer’s disease

In their recent paper, Soderstrom et al. confirmed their preliminary data suggesting that the CSF HVA:5-HIAA ratio was associated with psychopathic traits and, in particular, violent and aggressive behaviour with childhood onset and adult expression. These findings might indeed reflect changed dopaminergic activity, possibly as a result of serotonergic dysregulation. We hypothesise that their findings might be applicable to other brain disorders characterised by specific behavioural disturbances, including aggression and agitation. Indeed, since several studies have found associations between altered serotonergic neurotransmission and aggression in persons with dementia, it would be reasonable to propose that the CSF HVA:5-HIAA ratio might be associated with aggression in persons with dementia as well. To test this hypothesis, we performed an interim analysis on 102 out of 302 patients who were included in a prospective and longitudinal study on neurochemical and genetic correlates of behavioural and psychological signs and symptoms of dementia (BPSD). The data presented further support a general application of the interesting findings of Soderstrom et al.

Patients with various neurodegenerative forms of dementia were included in this prospective study, and were followed up by means of a neuropsychological and behavioural assessment every six months. In any case of death, brain autopsy was performed for neurochemical analysis as well as for neuropathological confirmation of the clinical diagnosis. All subjects and their caregivers gave informed consent to participation in the study, which was approved by the local ethics committee.

At baseline, behaviour was assessed by means of a battery of behavioural assessment scales which included the Behavioural Pathology in Alzheimer’s Disease Rating Scale (Behave-AD) and the Cohen-Mansfield Agitation Inventory (CMAI). Lumbar puncture was performed between 9 and 10 am for neurochemical analysis as well as for neuropathological confirmation of the clinical diagnosis. All subjects and their caregivers gave informed consent to participation in the study, which was approved by the local ethics committee.

Extensive radiculopathy: another false localising sign in intracranial hypertension

We read with interest the review by Larner on false localising signs. Among the various false localising signs described in patients with intracranial hypertension (ICH), radiculopathy is an important manifestation which is probably under recognised. Many authors have documented subtle features of radiculopathy in patients with isolated intracranial hypertension (IIH). The usual manifestations of radiculopathy in these cases were acral paraesthesias and backache and radicular pain. Rarely, motor deficits due to radiculopathy caused by ICHT have been described.

Obaid et al reported two patients with extensive radiculopathy due to ICHT; one individual had IIH and the other had cerebral sinus venous thrombosis. Both persons had papilloedema, marked visual impairment, and flaccid areflexic quadriparesis with normal MRI of brain, brainstem, and cervical spinal cord. The electrophysiological findings were consistent with radiculopathy. Both individuals initially received intravenous immunoglobulin for Guillain-Barre syndrome, without benefit, but they responded well to lumbo-peritoneal shunting. We also encountered two such cases with angiographically proven cerebral venous sinus thrombosis.

The most likely mechanism at the basis of radiculopathy appears to be similar to that of other cranial neuropathies in ICHT—that is, mechanical compression of nerve roots, due to elevated CSF pressure distending the subarachnoid space. Documented enlargement of spinal subarachnoid space and distended root pouches in a patient with radicular pain and areflexia due to IIH supports this view. Radiculopathy secondary to ICHT has been reported almost exclusively in patients with IIH or cerebral venous sinus thrombosis.

Other causes of ICHT may not induce such a diffuse increase in pressure in both intracranial and intraspinal compartments, and are unlikely to manifest as radiculopathy. The constellation of flaccid-areflexic quadriparesia and papilloedema may be misdiagnosed as Guillain-Barre syndrome with papilloedema. Careful analysis of the evolution of symptoms, estimation of CSF pressure, and appropriate vascular imaging should help to correctly identify the cause of ICHT.
Role of entacapone in later Parkinson’s disease not yet established

The study by Brooks and Sagar, along with a number of previous others, demonstrates benefit for the catechol-O-methyltransferase (COMT) inhibitor entacapone when compared with placebo in Parkinson’s disease (PD). However, this is insufficient evidence to justify the authors’ conclusion that “it appears logical to employ levodopa combined with entacapone routinely”. The important issue is not whether entacapone is more efficacious than placebo, but whether it is more or less clinically effective and cost effective than the other available treatments for patients with PD that is no longer adequately controlled by levodopa alone. Other available agents—including dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors—have also shown efficacy when compared with placebo. The paper would have benefited from a balanced discussion of the merits of entacapone compared with these other available treatment options. Such a discussion is likely to be inconclusive, however, as there is a dearth of reliable evidence on the best treatment for PD, at any stage of the disease, since very few trials directly comparing active treatments have been undertaken. Companies are reluctant to undertake such trials, as it is not in their commercial interests to risk studies that might show their product to be inferior to that of a competitor. For this reason, independent funded trials—such as the current PD MED trial in the UK—should be supported to provide the reliable evidence on comparative efficacy needed to enable clinicians to make informed treatment decisions. Analysis, presentation and interpretation of the results of independent studies are also likely to be more objective than those of commercial studies. The potential for bias in commercial trials has recently been highlighted by systematic reviews and journal editors—for example “systematic bias favours products which are made by the company funding the research” and “scientific studies can be manipulated in many ways to give results favourable to companies.”

There are problems with the trial reported by Brooks and Sagar, and these are common to many PD trials, which are generally of poor methodological quality. In a progressive condition such as PD, it is important to evaluate the long term effects of treatment, and six months follow-up is inadequate. The outcome measures used should reflect the impact of treatment on the patients’ own perception of their functioning and quality of life, not that of clinicians as with the Unified Parkinson’s Disease Rating Scale (UPDRS). It is unclear how well the data obtained from on-off diaries correlates with global quality of life, and how to treat (ITT) analysis was not performed, since patients who withdrew from treatment were excluded from the analysis—ITT analysis requires such patients to be followed up and included in the analysis according to the arm to which they were allocated even if they have withdrawn from allocated therapy. Nearly 50% more patients (24.1% vs 16.5%) dropped out of the entacapone arm than from the placebo arm and, in progressive diseases such as PD, dropout bias tends to favour the active treatment. Thus, although COMT inhibitors are welcomed as addition to the treatment options in PD, large, rigorously conducted comparative trials, assessing the long term impact on patient-rated measures of overall quality of life, are still needed to define their role in routine clinical practice.

K Wheatley, N Ives, R Gray
University of Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK

C Clarke
City Hospital, Birmingham, UK

Correspondence to: Professor K Wheatley, Birmingham Clinical Trials Unit, University of Birmingham, Park Grange, 1 Somerst Road, Edgbaston, Birmingham B15 2RS, UK; k.wheatley@bham.ac.uk

Competing interests: We are investigators in the PD MED trial and thus have a vested interest in obtaining objective evidence on the best treatment for PD. CC has received honoraria, consultancy fees, and travel expenses from the manufacturers of many of the drugs discussed.

References

Portal-systemic shunts, manganese, and parkinsonism

I read with interest the article by Yoshikawa and colleagues. The authors reported the case of a 44 year old woman with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) involving the liver, who had raised serum concentrations of manganese, hyperintense areas in the basal ganglia on T1 weighted magnetic resonance images, and levodopa unresponsive parkinsonism. Naturally, I agree that the parkinsonism in this case is most probably related to portal-systemic (portal-venous) shunts. There are, however, two points that deserve clarification.

First, it is not entirely clear whether their fig 2 (left panel) shows portal-systemic or arteriovenous shunts. The authors say that the figure shows a selective angiogram of the superior mesenteric artery. If that were the case, there should not be a “feeding artery” involved in the intraparenchymal shunts (as they state in the legend to fig 2). Instead, the figure would show the portal phase of the angiogram and show a feeding artery (the hepatic artery) and arteriovenous (not portal-systemic) shunts. Interestingly, there is evidence to suggest that both types of shunt are common in patients with portal venous complications in the presence of an intact (or mostly preserved) hepatic parenchyma. Thus excessive quantities of potentially toxic substances (for example, manganese) passing directly from the gut to the systemic circulation through portal-systemic shunts could be rapidly cleared by a normal liver as long as the hepatic blood flow is adequate.

Second, Yoshikawa and colleagues claim that the parkinsonism of their patient was induced by manganese. While this is a reasonable working hypothesis, the authors provide no direct evidence supporting such a statement. The fact that manganese levels were raised does not necessarily imply that manganese played a key role in the pathogenesis of parkinsonism. Indeed, their patient lacked many clinical features often seen in cases of manganese induced parkinsonism (for example, cock walk and propensity to fall backwards).

Levodopa unresponsive parkinsonism is a well known manifestation of chronic non-Wilsonian hepatocerebral degeneration. Although blood concentrations of ammonia were within the normal range in the case reported by Yoshikawa and colleagues, the possibility of manganese passing directly from the gut to the systemic circulation through portal-venous shunts was not investigated.

R de la Fuente-Fernández
Division of Neurology, Hospital A Maricla, Estrada San Pedro-Cataheira s/n, 15405 Feral, A Coruña, Spain

Correspondence to: Dr Raúl de la Fuente-Fernández, rfuente@medynet.com

References

Authors’ reply

We are pleased to have an opportunity to comment on the important issues raised by Dr de la Fuente-Fernández regarding a case of hereditary haemorrhagic telangiectasia.
with parkinsonism. Raised serum manganese combined with the abnormal findings in cranial magnetic resonance imaging and abdominal angiography were the rationale for our conclusion that the parkinsonism in our patient was induced by manganese that had accumulated because of portal-systemic shunting.

Ah, the angiogram: the angiogram of the superior mesenteric artery presented in our manuscript showed a dilated feeding artery, a dense mottled hepatogram, and early filling of the hepatic vein. These findings concerned the arterial phase. The intrabiliary arterovenous shunts were definite diagnostic evidence of hereditary haemorrhagic telangiectasia but not of portal-systemic shunts.

We therefore agree with Dr de la Fuente-Fernández that we should have presented another angiogram in the portal phase showing a hypoplastic portal vein with abnormal vessels between the mesenteric and inferior vena cava to confirm the portal-systemic shunt.

About the parkinsonism: after the failure of treatment by levodopa, we took other measures to relieve the parkinsonism; for example, we persuaded the patient to avoid manganese-rich foods such as blueberries. Fortunately, her serum manganese gradually decreased below the normal upper limit during the next six months, and her neurological symptoms became less prominent.

All evidence of parkinsonism in inverse proportion to serum manganese concentrations suggests that the parkinsonism in this case may have been caused by manganese accumulation, and that the patient was in the early stage of manganese intoxication in which neurological symptoms were incomplete and partially reversible.

About transient hyperammonaemia: we searched for cases of hyperammonaemia related parkinsonism, and finally found a case with portal-systemic encephalopathy and parkinsonism which disappeared after treatment of the portal-systemic shunting.1 The mechanism of parkinsonism in that case is actively open to debate, as hyperammonaemia is generally thought to cause disturbance of consciousness or negative symptoms rather than parkinsonism. We do not deny the possibility that our patient may have had a transient increase in serum ammonia, though it seems unlikely when there had never been a disturbance of consciousness.

K Yoshikawa, M Nakagawa
Department of Neurology, Research Institute for Neurological Diseases and Geriatrics, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Correspondence to: Dr K Yoshikawa, kyouik@koto.kpu-med.ac.jp

Reference

Intraventricular assessment of preoperative electrographic recordings

The paper by Song et al describes the placement of intraventricular arrays with endoscopic assistance for preoperative electrogaphic recordings for epilepsy surgery. The 4.2 mm outer diameter rigid endoscope was introduced up to the temporal ostium from where the arrays were advanced until a point of resistance was felt.

In our paper we reported the use of a 1.2 mm outer diameter semi-rigid endoscope to explore the contents of the ventricles prior to electrode placement, with direct visual assessment of the final electrode position, which helped us obtain appropriate pre-resection electrographic recordings. Perhaps it would be more convenient to use semi-rigid endoscopes or slim fibrescopes to fully visualise the ventricle as well as flexible arrays to avoid electrode displacement resulting in unintentional cerebral lesions.

O H Jiménez
Dept Neurosurgery, Hospital General “Dr. Miguel Silva”, Secretaría de, Salud de Michoacán, Mexico

N Nagore
Dept Neurosurgery, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, CP 58000, Mexico

Correspondence to: Dr O Jimenez, ohjv@yahoo.com.mx

References

Parkinsonism and persistent vegetative state after head injury

Matsuda et al recently reported three patients with a persistent vegetative state (PVS) after severe head injury who, after recovering from prolonged disturbance of consciousness, presented parkinsonian features (mainly rigidity and hypokinesia) which improved after levodopa treatment.1 MRI studies showed lesions in the dorsolateral midbrain and cerebral peduncles suggesting axonal injury involving the dopaminergic system (substantia nigra and ventral tegmental area). Similar observations were made in a series of 125 patients with severe vegetative state following head injury (survival time 1–10 years). Nineteen of 49 patients surviving in fully developed or mild recovery stages of PVS initially presented with severe to moderate, mainly symmetrical, parkinsonian symptoms (amimia, rigidity, hypokinesia, and convergence disorders). Following levodopa treatment, 11 patients showed incomplete and full improvement of both the PVS and parkinsonism, while four patients showed complete recovery from both syndromes. However, in 15 patients—despite good recovery from the initial PVS and other neurological symptoms (spasticity, frontal and cerebellar symptoms), and long term levodopa treatment—a progressive parkinsonian syndrome (rigidity, hypokinesia) developed in six patients: this was associated with unilateral or bilateral resting tremor. In MRI studies done in 34 patients, 32 showed unilateral or bilateral lesions in the midbrain involving both the dorsolateral tegmentum and the cerebral peduncle.2

Neuropathological studies were undertaken in 32 patients surviving without essential improvement of the PVS for at least two months after head injury. Parkinsonian syndromes were severe in seven, moderate in five, and mild in four.3 In addition to older haemorrhages or necroses in the putamen and the globus pallidus (n = 6), globus pallidus and thalamus (n = 8), all brains revealed multiple lesions in the rostral brain stem with unilateral or bilateral focal lesions in the substantia nigra, vascular lesions in the lateral and/or lateral midbrain in seven, and symmetrical post-anoxic cellular depletion and gliosis or unilateral necroses in the substantia nigra in one case each. In nine cases, there was a good correlation between the severity of clinical parkinsonian signs and the severity and extent of nigral lesions; three patients showed severe parkinsonian signs associated with only mild nigral damage, but there was severe bilateral damage to the globus pallidus in two. In four patients the expression of clinical parkinsonian signs was more severe than the anatomical lesions, in particular the damage to the substantia nigra. The distribution pattern of the brain stem lesions correlated with the sequelae of transtentorial shifting caused by increased intracranial pressure; direct or “primary” traumatic lesions to the oral brain stem usually cause acute death, as seen in two young men with rupture of the diencephalon and acute haemorrhage into the substantia nigra or midbrain following severe and acute fatal head injuries. However, in rare patients with long-term survival following head injury, symmetrical necrosis of the substantia nigra without a clinical parkinsonian syndrome has been reported.4

The clinical phenotype of post-traumatic parkinsonism often resembles that in post-encephalic parkinsonism, both showing akinnesia, rigidity, hypomimia, rare tremor, and optomotor and vegetative disorders. Both the lesion pattern and the therapeutic efficacy of long term levodopa treatment suggest a dysfunction of the striato-nigral dopaminergic system which, however, may show progressive decompensation in some patients with long lasting PVS after severe head injury.

K A Jellinger
Institute of Clinical Neurobiology, Kenyongasse 18, A-1070 Vienna, Austria

Correspondence to: Dr Kurt A Jellinger, kurt.jellinger@univie.ac.at

REFERENCES

Authors’ reply

We greatly appreciate the thoughtful comments offered by Dr Jellinger, and his interest in our report of three cases in a persistent vegetative state (PVS) after severe head injury.
injury, who recovered from a prolonged disturbance of consciousness after they were given levodopa.

Dr Jellinger reports that in cases of prolonged post-traumatic coma the brains showed multiple lesions of primary and secondary traumatic origin and that the highest incidence of lesions was found in the rostral brain stem. These were considered to be almost exclusively of secondary origin, resulting from cerebral and peripheral circulatory disorders, post-traumatic oedema, and increased intracranial pressure. Primary (direct) traumatic lesions to the rostral brain stem usually cause acute death. In contrast to this report, the brain stem injuries in our cases suggested by MRI may have been the primary traumatic lesions. All these cases showed high intensity lesions in the dorsolateral midbrain on T2 weighted MRI.1 These findings implied that the midbrain was injured by tentorial compression induced by translatory and rotatory acceleration when the cranium was struck in its sagittal axis, or by postero-lateral damage. MRI findings, particularly in the acute stage, are useful for evaluating primary brain damage.2

Furthermore, another distinctive feature of our cases was that the anatomical distribution of the lesions was not multifocal but was localised in the cerebral peduncle or the dorsolateral midbrain, implying diffuse axonial injury involving the substantia nigra or the ventral segmental area.3 The neuropathological findings, the clinical features of extra-pyramidal dysfunction, and the efficacy of levodopa treatment all strongly suggest that the dopaminergic pathways were selectively damaged and caused defects in the nigrostriatal, mesocortical, or mesolimbic system. As Dr Jellinger indicates, progressive decompensation in levodopa treatment is a considerable problem. However, not all our patients have required permanent medication; an example is case 1 in our report, whose recovery was sustained even after the levodopa treatment was discontinued. Some patients may need levodopa only as a trigger agent at the start of treatment to interrupt the vicious cycle of exhaustion of neurotransmitter. However, discriminating which cases fall into this category is very difficult and withdrawal of medication involves ethical problems.

In recent neuropathological and radiological studies on PVS after traumatic brain injury,4–6 the most common structural abnormalities were diffuse axonal injury involving the corpus callosum, the dorsolateral aspect of the rostral brain stem, and the thalamus. Although the clinical features will vary in such cases, a take-home message which we learned from our three cases is that in any group of patients with PVS after severe head injury there may be some whose dopaminergic systems may have been selectively damaged; such individuals may respond to levodopa treatment. It is necessary to accumulate a great deal more clinical experience and data to elucidate the pathogenesis and pathophysiological mechanisms of post-traumatic PVS. We respect Dr Jellinger’s careful observations and descriptions of his cases of prolonged post-traumatic coma, and look forward to further views from him on this topic.

W Matsuda, Y Komatsu
Department of Neurosurgery, Tsukuba Medical Centre Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki 305-0005, Japan

Correspondence to: Dr Wakoto Matsuda, wakm@mmu.biglobe.ne.jp

References

Year book of neurology and neurosurgery 2003


Every year, countless journals publish myriad neurology and neurosurgery papers. There is immense attrition in the notion of a single volume yearbook that selects and comments on the best. So, how well does the Yearbook of neurology and neurosurgery succeed in informing about significant advances in knowledge over the past year in this specialty area for 2003? The editors draw their selection from a survey of 500 journals, with something from most of those with big impact. Thirty seven associate editors assisted by reviewing the various subspecialty areas; of these all except 11 come from North America, of whom 9 are neurosurgeons rather than neurologists, an intriguing imbalance.

Papers selected cover every conceivable subspecialty, and sometimes the inconceivable. New gene mutations abound, illuminating pathogenesis, and about informed consent in neurosurgery, and we are treated to pictures of new cranial remodelling devices for treating craniostenosis. To provide a critical review of such a diversity of subject matter would be a monumental task. All one can do is to congratulate the editors for highlighting a selection of topics that opens one’s eyes to the dazzling diversity of our specialty. Nevertheless, you would not go to a yearbook for a comprehensive review of developments in a particular subspecialty. Therefore, this is essentially armchair reading, and none the less useful for that.

Each article is summarised in half a page or so under the headings introduction (or background), methods, results, and conclusion. This is followed by a brief editorial comment that is often interesting and pithy. At least some of this signed editorial comment is derived verbatim, or with only minor paraphrasing, from editorial comment in the journal originally publishing the chosen paper. So whose opinions are you really reading in the yearbook?

Although interestingly informative outside one’s subspecialty, one does need to ask whether the concept of a single volume yearbook isn’t becoming submerged by the sheer volume of potentially eligible papers published each year. And, although this 2003 yearbook arrived on my desk in December 2003, it predominately covers papers published in 2001, with some from early 2002, and an occasional hangover from 2000. So, it isn’t that up to date. I guess libraries will buy it, partly out of habit. But for individuals, £74 is a steep price for neurological coffee table reading.

M Donaghy

Reference

Catatonia: a clinician’s guide to diagnosis and treatment


This nicely produced book reviews one of the historically most interesting, but clinically still very important, disorders of neuropsychiatry. Catatonia, described by Kalinbau in the latter half of the 19th century, was hijacked by Kraepelin to be incorporated into his concept of dementia praecox, and almost disappeared from the literature in the first half of the 20th century, being finally eclipsed by the introduction of effective psychotropic drugs thereafter. But, as Fink and Taylor explore here, catatonia as a diagnosis is still a diagnostic challenge, with causes far beyond schizophrenia and a syndrome with effective treatment, notably, but not exclusively electroconvulsive therapy (ECT).

For those interested in the cerebral basis of psychiatry, a condition with the main presenting signs of mutism, immobility, negativism, posturing, stereotypy, and echo-phenomena cannot fail to attract attention, and the many faces of catatonia (title, chapter 3) are an olla podrida of neuro-psychiatry. It is refreshing to find reference to Leonard’s work and the ‘dumb cypresses’ in a text from American authors, who are thoroughly appreciative of the European literature on their subject, and shyly critical of DSM-IV. Their overall conclusions are clear: Catatonia is a condition of S-L syndrome, neuropsychiatric malignant syndromeis malignant catatonia, catatonia is not usually associated with schizophrenia, and it is a syndrome of motor dysregulation with a good prognosis—if identified and treated early. This book is a pleasure to read, but should be on the imperative reading list for all psychiatric trainees to inform them about the history of their discipline, the importance of neuropsychiatry, and how to write clearly.

M R Trimble

www.jnnp.com
The New Oxford textbook is the latest and largest of the Oxford textbook of psychiatry to be published, and has been widely praised by neurologists and neurosurgeons. The book is the first choice for postgraduate education, although it is only suitable for libraries. This would be a price of £125 even for the paperback. This is a Rolls Royce of a book, and it is used to respond to a light flashed in either visual field differs according to the kind of tissue and tissue at risk of irreversible damage. The text is tempered with some discussion of the role of imaging in any diagnostic process. The approach to an MR scanner with diffusion imaging would suggest. Although mainly concerned with the cognitive neuroscience of the corpus callosum, it also covers single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging as well and provides a useful guide to an MR scanner with diffusion imaging. The authors express personal views and opinions. The authors are accompanied by commentaries and editorial comment, giving a flavour of the debates and controversies in the field. Perhaps reflecting the long interval between the original conference and this book, more recent studies that use functional neuroimaging techniques to investigate callosal function are relatively poorly represented. However, there is still much of interest in this otherwise comprehensive volume. The chapters generally have a basic scientific focus, but chapters on multiple sclerosis, dyslexia and alexia, schizophrenia, and attention deficit hyperactivity disorder also contain much that will interest the practicing clinician.

G Rees

Magnetic resonance imaging in stroke


This book does much more than its title would suggest. Although mainly concerned with magnetic resonance imaging (MRI) in stroke, the text actually covers single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging as well and provides a useful guide to an MR scanner with diffusion imaging. It would be able to correctly diagnose a TIA using this new classification. Not only that, but the diagnosis of TIA might be dependent on the ability of the local radiologist or clinician to spot subtle features of recent ischaemia on diffusion imaging. Although this clearly represents a personal opinion expressed by the authors, it is a standard on changing a classification that is so fundamental to stroke epidemiology and clinical practice is that only those with access to an MR scanner with diffusion imaging would be able to correctly diagnose a TIA. Its use is digestible and yet also a useful reference. At £80.00 I think compared with other books on MR and stroke it represents good value for money.

J M Wardlaw

Cortex and mind: unifying cognition


Joaquin Fuster is a distinguished American neuroscientist whose work has explored the neurophysiology of cognition, largely in animals, but with the ultimate goal of understanding how the human mind is implemented in the brain. His own research has focused particularly on the role of memory, revealing "memory" cells in the prefrontal cortex that help to retain the information an animal must "keep in mind" if it is to access it appropriately after a delay—like the position of a covered well contents. At the same time, prefrontal memory cells are a key component of an extensive cortical network required to maintain working memory, which also involves...
The bard on the brain—understanding the mind through the art of Shakespeare and the science of brain imaging


One of the great challenges of popular science writing is to convey a coherent and consistent impression of scientific ideas while avoiding confusing, specialist terminology. The most useful tools for this task are metaphor and pictures. The Dana Press, publisher for the Charles A Dana Foundation, has as its mandate “the provision of information about the personal and public benefits of brain research”. With The bard on the brain, they have chosen to use the voice of William Shakespeare, the master craftsman of metaphor, to introduce the areas of human cognition that have attracted the most attention in recent functional imaging research. The authors’ approach is that of the bard, the authors explain, “Shakespeare’s genius derives from his keen insight into the human mind” and that, in functional imaging, “brain scientists finally have the means to address questions that Shakespeare had eloquently put forward four centuries ago”. The book is a play in seven acts, each of which tackles a different field of research in cognitive neuroscience, including perception, language, the inner world of memory and emotions, and the breakdown of the mind in certain neuropsychiatric disorders. Within these acts, each examines a particular feature of the mind and illustrates how Shakespeare dissected and explored it in his own laboratory—the theatre. The scene opens with a quotation from Shakespeare and a brief synopsis of the plot before moving on to discuss the hard neuroscience underlying this cognitive phenomenon as revealed by the latest neuroimaging techniques. For example, in discussing the role of the frontal lobes in attention shifting and the planning of behaviour, the example is chosen of Prince Hal, the wayward, youthful heir of Henry IV who purposely turns from the influence of Sir John Falstaff and his frivolous drinking companions in order to develop the resolve and strength of character which will later serve him well as King Henry V. This transformation is compared with the case of Phineas Gage, the 19th century rail worker who survived a dramatic penetrating injury to his cranium but consequently displayed a remarkable alteration in his personality. Recent computed tomography reconstructions of Gage’s skull by Antonio Damasio and his colleagues have clearly delineated the passage of the three foot tamping iron through the frontal cortex—the area “responsible for the functioning of what we call a moral sense”. The concept is an entertaining one and the authors have worked hard to bring it to life. The target audience presumably consists of people with no specialist knowledge of either Shakespeare or neurology and, if this is so, the reader will find the information to be found here—particularly the closing chapters on language and intelligence—and anyone who is used to locating cortical networks on colourful scans will find cause for thought in these pages.

The concept of metaphor continues to hold sway in the public’s imagination, and there are even signs of a return to this method of teaching. The old medical text-books—a list of symptoms with a diagnosis at the end—have given way to a more patient-focused approach. Patients today want to understand what is happening to them, not just to know that they have a disease. The concept of metaphor speaks to this desire. This is illustrated by the title page of the book, which features a painting of a man in a wheelchair, with the words “The bard on the brain—understanding the mind through the art of Shakespeare and the science of brain imaging”. The author, Paul M Matthews, is a professor of neurology at the University of California, San Francisco, and the book is aimed at a general audience, with no prior knowledge of neurology required. It is written in a clear, accessible style, and the author succeeds in making the science of brain imaging accessible to the lay reader. The book is divided into seven sections, each focusing on a different aspect of the brain, such as memory, language, and emotion. Each section begins with a brief introduction to the topic, followed by a discussion of the latest research findings. The author uses language that is easy to understand, and he avoids jargon and technical terms. The book is well-organized, with each section containing a number of chapters that build on each other. The author also includes a number of case studies, which help to illustrate the points he is making. Overall, the book is a valuable resource for anyone interested in the science of brain imaging, and it is highly recommended for all professionals in this field.
testing, common neurological presentations, for example headache and weakness, specific neurological conditions, for example multiple sclerosis and cerebrovascular disease, neurological trauma, paediatric neurological emergencies, pregnancy related neurological emergencies, neurotoxicology, and brain death. So, it attempts a comprehensive coverage.

The editors consider it to be symptom based, although this is not always achieved. It has many tables, good illustrations, and management of algorithms with “pearls and pit falls” at the end of every chapter. The neurological examination is done poorly, particularly the cranial nerves. This needs to be done with pictures of the lesions, their causes, and the anatomy, based around the common emergency presentations in A&E. Although neurologists would disagree with some of the advice given, most of the text is reliable and clear. (For instance, in the chapter on myasthenia gravis, it states “useful gauges include pulse oximetry, peak expiratory flow and PCO2 measurement”, which are all poor gauges of impending ventilatory failure and vital capacity is the most important measurement in this respect.) The most disappointing feature is that the chapters are not adequately focused on emergency conditions. The chapter on movement disorders covers virtually the whole spectrum of chronic movement disorders without specifically concentrating on the common emergency presentations, such as drug induced dystonia with oculogyric crisis and hemiballisms, which are likely to come to A&E. Unfortunately the editors and authors have failed to produce a sufficiently concise account of emergency conditions to make this book really useful. It needs to be much briefer and appropriately focused to achieve its aim and it would be better as a pocket account of emergency conditions to make

hope alone and Professors Emery and Muntoni have elegantly summarised present management options.

The second edition was published in 1986, a matter of months before the identification of the gene involved in the disease process and its protein product dystrophin. Within a few years it became apparent that dystrophin and dystrophin associated proteins have a fundamental role in various forms of muscular dystrophy, and for a while it looked as if there might be a common mechanism of membrane fragility due to dysfunction of these membrane associated proteins. Then abnormal cytosolic proteins were found in some forms of limb girdle dystrophy and it became clear that there was no simple single disease mechanism. Despite that, altered function of membrane proteins is clearly of fundamental importance in many dystrophies and Muntoni has been at the forefront of recent discoveries relating to altered glycosylation of the membrane protein z-dystroglycan in various forms of congenital and adult onset limb girdle dystrophies.

There is no need to describe the individual chapters in detail. In brief, the monograph covers the history of the disease (Emery being a noted medical historian), clinical features, differential diagnosis, molecular pathology, pathogenesis, genetic counselling, and management. Emery is retired from clinical practice but the clinical setting is kept up to date by his being joined by Muntoni for this timely third edition.

All those involved in the management of DMD will find something of value in this book. Some patients and families may also want to dip into it. Those interested in the history of medical science, the evolution of modern genetic and molecular techniques, will find it a fascinating story.

Let us hope that a fourth edition, detailing the successes of genetic engineering, will not be too far off, but in the meantime there is much that can be done to alleviate the consequences of this truly awful condition.

Duchenne muscular dystrophy, 3rd edn


Quite simply, this monograph is essential reading for anybody involved with this devastating condition, and indeed for those involved with any form of muscular dystrophy, whether in the clinic or in the laboratory. Duchenne muscular dystrophy (DMD) is the archetypal dystrophy. It is because the clinical course is so stereotyped that it was the first of the dystrophies to be defined clearly, over a century ago. The historical journey from the first clinical descriptions to our present state of knowledge forms the core of this book, with side branches relevant to the identification of other specific forms of dystrophy, particularly the limb girdle dystrophies. The nihilist may suggest that all of this knowledge has as yet failed to find a cure, but for the clinicians intimately involved with these patients we can now do more than ever to provide an improved quality of life. There is of course great hope that “genetic engineering” will lead to a cure, but patients and their families cannot live on

Mental and behavioral dysfunction in movement disorders


It was not long ago that the basal ganglia were confidently asserted to have no influence on cognition, and to have only motor functions. This was the province of neurology, and the concept that they might be involved in disorders behaviour other than that related to as movement disorders was an anathema to generations of neurologists.

As Goetz notes, in the introduction to this nicely produced book, this view ignored over a 100 years’ of clinical observation, and much subsequent work, theoretical, clinical, neurochemical, and neuroanatomical, all of which underlie the central role of the basal ganglia structures in regulating behaviour, in its widest sense, and hence the association between movement disorders and cognitive and behavioural dysfunction.

The openers in this text are with neuroanatomy and neurochemistry, rightly so since the impact of the discovery of dopamine and the unveiling of the new neuroanatomy of the limbic forebrain, have fundamentally altered the way we think about the brain and its functions, and should profoundly influence clinical thinking. A chapter on the cerebellum is also included in the opening section.

The book then contains chapters on two main themes, cognition in movement disorders, including the long controversial area of links with dementia, and the neuropsychiatry of movement disorders. The main diseases discussed are the obvious eponymous ones of Parkinson’s, Huntington’s, and Gilles de la Tourette, as well as cortico-basal degeneration. There are some curious omissions, Wilson’s disease, Sydenham’s chorea, and supranuclear palsy, among others. The cognitive problems embrace such topics as speech disorders and apraxias, and include chapters on animal models as well as clinical research.

The section on neuropsychiatric aspects is laid out rather differently and less systematically. A chapter on mood disorders and the pallidum, another on depression and the basal ganglia, another on psychosis and mood disorders in Huntington’s disease, some disease oriented, others anatomically based. Nevertheless, the individual chapters are, for the most part, well written, and included are contributions on REM sleep behaviour disorder, psychogenic movement disorders, and obsessive compulsive disorder. A separate section is devoted to quality of life studies.

The book is a timely reminder of the growth of interest in and the clinical importance of neuropsychiatry, and quite some space in the text is given to treatment and management issues. No longer can the basal ganglia simply be viewed as structures sub-serving motor function, they represent drives and affects which are re-represented cortically and which propel our very being.

D Hilton-Jones

CORRECTIONS
doi: 10.1136/jnnp.2003.029074cor1

In the review by Rockwood in the May issue of JNNP (K Rockwood. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75 677–85) there is an incorrect entry on the x axis each of the tables in figure 1. The sixth entry should read 0.25, instead of 0.3. The corrected table can be viewed at http://www.jnnp.bmjjournals.com/cgi/content/full/75/6/677/DC1

doi: 10.1136/jnnp.2003.034876corr1

The authorship list of the letter entitled emotion process in the minimally conscious state, by Bekinschtein et al (JNNP May 2004;75:788), was incorrectly printed as T Bekinschtein, J Niklison, L Sigman, F Manes, R Leiguarda, J Armony, A Owen, S Carpintiero, L Olmos. The correct order is as follows: T Bekinschtein, R Leiguarda, J Armony, A Owen, S Carpintiero, J Niklison, L Olmos, L Sigman, F Manes.